Virological and immunological effects of antioxidant treatment in patients with HIV infection

European Journal of Clinical Investigation

Volumn 30, Issue 10, 2000, Pages 905-914

  Muller F ^a,c   Svardal, A M ^b   Nordoy I ^a   Berge, R K ^b   Aukrust, P ^a   Froland S S ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Glutathione; HIV; N acetylcysteine; Oxidative stress; Vitamin C

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; ASCORBIC ACID; GLUTATHIONE; NEOPTERIN; THIOL DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS RNA;

ABDOMINAL DISCOMFORT; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CYTOKINE RELEASE; DRUG MEGADOSE; GLUTATHIONE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MALE; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PILOT STUDY; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIRUS REPLICATION;

ACETYLCYSTEINE; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIGENS, CD14; ANTIOXIDANTS; ANTIVIRAL AGENTS; APOPTOSIS; ASCORBIC ACID; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CYSTEINE; DIPEPTIDES; DRUG THERAPY, COMBINATION; GLUTATHIONE; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; MONOCYTES; NEOPTERIN; OXIDATIVE STRESS; PILOT PROJECTS; RECEPTORS, TUMOR NECROSIS FACTOR; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033787687     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2000.00727.x     Document Type: Article

References (51)

1. The role of glutathione in lymphocyte activation I. Comparison of inhibitory effects of buthionine sulfoximine and 2-cyclohexene-1-one by nuclear size formation
2. Glutathione augments the activation of cytotoxic T lymphocytes in vivo
3. Requirement of thiol compounds as reducing agents for IL-2 mediated induction of LAK activity and proliferation of human NK cells
4. Glutathione
5. The thiols glutathione, cysteine, and homocysteine in human immunodeficiency virus (HIV) infection
6. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals
7. Decreased serum glutathione with normal cysteine and homocysteine levels in patients with AIDS
8. Intracellular glutathione levels in T-Cell subsets decrease in HIV-infected individuals
9. CD4 and CD8 T-Cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses
10. Increased levels of oxidized glutathione in CD4+ lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1 infection
11. Intracellular thiols regulate activation of nuclear factor kappaB and transcription of human immunodeficiency virus
12. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappaB transcription factor and HIV-1
13. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N.acetylcysteine
14. Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells
15. Comparative study of the anti-HIV activities of ascorbate and thiol-containing reducing agents in chronically HIV-infected cells
16. Glutathione and N-acetylcysteine suppression of human immunodeficiency virus replication in human monocyte/macrophages in vitro
17. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine
18. Glutathione precursor and antioxidant activities of N-acetylcysteine and oxothiazolidine carboxylate compared in in vitro studies of HIV replication
19. Thiol suppression of human immunodeficiency virus type-1 replication in primary cord blood monocyte-derived macrophages in vitro
20. In vitro inactivation of human immunodeficiency virus by ascorbic acid
21. NF-kappa B-independent suppression of HIV expression by ascorbic acid
22. Glutathione ascorbic acid antioxidant system in animals
23. Glutathione, ascorbate, and cellular protection
24. N-Acetylcysteine - A new approach to anti-HIV therapy
25. Reactive oxygen intermediates and human immunodeficiency virus (HIV) infection
26. Cysteine and glutathione deficiency in AIDS patients - A rationale for the treatment with N-acetylcysteine
27. Reactive oxygen species, antioxidants, and acquired immunodeficiency syndrome. Sense or speculation
28. 1993 revised classification for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
29. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma
30. Elevated plasma concentration of reduced homocysteine in patients with human immunodeficiency virus infection
31. Impaired in vitro survival of monocytes from patients with HIV infection
32. Rapid immunomagnetic phenotyping of cells
33. Decreased levels of total and reduced glutathione in CD4 (+) lymphocytes in common variable immunodeficiency are associated with activation of the tumor necrosis factor system: Possible immunopathogenic role of oxidative stress
34. Determination of reduced, oxidized, and protein-bound glutathione in human plasma with precolumn derivatization with monobromobimane and liquid chromatography
35. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias
36. Direct immunomagnetic quantification of lymphocyte subsets in blood
37. Glutathione depletion in HIV-infected patients - Role of cysteine deficiency and effect of oral N-acetylcysteine
38. Supplementation of N-acetylcysteine fails to increase glutathione in lymphocytes and plasma of patients with AIDS
39. Effect of N-acetylcysteine (NAC) treatment on HIV-1 infection: A double-blind placebo-controlled trial
40. Glutathione deficiency is associated with impaired survival in HIV disease
41. Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV1-infected patients: A randomized, controlled pilot study
42. Clinical pharmacokinetics of N-acetylcysteine
43. Inhibition of HIV-1 replication and NF-kappaB activity by cysteine and cysteine derivatives
44. Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection - Correlations to clinical, immunologic, and virologic parameters
45. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis
46. N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein (a) levels
47. HIV-protease inhibitors
48. Advances in HIV/AIDS therapy
49. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease
50. Resistance to HIV protease inhibitors
51. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease